-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on NeoGenomics, Raises Price Target to $19

Benzinga·07/29/2026 09:39:57
Listen to the news
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $15 to $19.